RxDoctor Payments Data

Tammy Dawson

Psychiatric/Mental Health · New Castle, PANPI 1134682628

Payments from drug & device makers

$965in general payments, 2019–2025

Across 44 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$310
  • Supernus Pharmaceuticals, Inc.$134
  • Otsuka America Pharmaceutical, Inc.$121
  • AbbVie$119
  • Sunovion Pharmaceuticals Inc.$89
  • Takeda Pharmaceuticals U.S.A., Inc.$52
  • plus $142 from 5 others

What the payments were for

  • Food & beverage$91795%
  • Education$495%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$965 in reported general payments places this provider in the 60th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$7,662
Medicare patients
36
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate19$147,565
RexultiBrexpiprazole26$36,042
TrintellixVortioxetine Hydrobromide27$12,747
AzstarysSerdexmethylphen/Dexmethylphen12$5,355
Aripiprazole103$5,308
Quetiapine Fumarate ErQuetiapine Fumarate37$2,269
Buspirone Hcl140$2,014
Divalproex Sodium ErDivalproex Sodium56$1,699
Bupropion XlBupropion Hcl46$1,649
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine36$1,438
Risperidone65$1,257
Duloxetine Hcl107$1,155
Sertraline Hcl132$1,117
Escitalopram Oxalate114$1,080
Venlafaxine Hcl ErVenlafaxine Hcl77$851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$121$36,04226 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$52$12,74727 claims
Corium, LLCAzstarys$19$5,35512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in New Castle

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →